Screener
CURE vs HIBS
Direxion Daily Healthcare Bull 3X Shares vs Direxion Daily S&P 500 High Beta Bear 3X Shares
Key differences
- CURE costs 0.12% less per year.
- CURE is significantly larger than HIBS — larger funds tend to be more liquid and less likely to close.
- CURE follows a leveraged strategy; HIBS uses inverse.
- Over the last 3 years, CURE has delivered higher annualized returns.
- CURE has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| CURE | HIBS | |
|---|---|---|
| Annual cost (TER) | 0.94% | 1.06% |
| Fund size (AUM) | $138M | $19M |
| Since | 2011 | 2019 |
| Dividend yield | 1.33% | 7.92% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | leveraged | inverse |
| CAGR 1Y | +31.7% | -80.6% |
| CAGR 3Y | +0.8% | -62.8% |
| CAGR 5Y | +0.7% | -52.3% |
| Sharpe 3Y | 0.14 | -0.97 |
| Volatility 1Y | 42.92% | 67.54% |
| Max drawdown | -69.19% | -99.98% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to CURE and HIBS
Explore further